Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop.
(GIP RA)
Finerenone
Glucagon-like peptide-1 receptor agonist (GLP-1 RA)
Glucose-dependent insulinotropic polypeptide
Network meta-analysis
Randomized controlled trial
Sodium glucose cotransporter 2 inhibitor
Tirzepatide
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
13 10 2023
13 10 2023
Historique:
received:
17
06
2023
accepted:
14
09
2023
medline:
23
10
2023
pubmed:
14
10
2023
entrez:
14
10
2023
Statut:
epublish
Résumé
In recent years, several novel agents have become available to treat individuals with type 2 diabetes (T2D), such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i), tirzepatide, which is a dual glucose-dependent insulinotropic polypeptide receptor agonist (GIP RA)/glucagon-like peptide-1 receptor agonist (GLP-1 RA), and finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA) that confers significant renal and cardiovascular benefits in individuals with (CKD). New medications have the potential to improve the lives of individuals with diabetes. However, clinicians are challenged to understand the benefits and potential risks associated with these new and emerging treatment options. In this article, we discuss how use of network meta-analyses (NMA) can fill this need.
Identifiants
pubmed: 37833776
doi: 10.1186/s12933-023-01993-3
pii: 10.1186/s12933-023-01993-3
pmc: PMC10576408
doi:
Substances chimiques
Sodium-Glucose Transporter 2 Inhibitors
0
Glucagon-Like Peptide 1
89750-14-1
Glucagon-Like Peptide-1 Receptor
0
Hypoglycemic Agents
0
Types de publication
Letter
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
277Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Diabetes Care. 2020 Apr;43(4):726-733
pubmed: 32079627
Eur Heart J. 2022 Feb 10;43(6):474-484
pubmed: 35023547
Intern Emerg Med. 2017 Feb;12(1):103-111
pubmed: 27913917
BMJ. 2020 Nov 11;371:m3900
pubmed: 33177059
BMJ. 2023 Apr 6;381:e074068
pubmed: 37024129
N Engl J Med. 2022 Jul 21;387(3):205-216
pubmed: 35658024
Diabetes Res Clin Pract. 2021 Jul;177:108870
pubmed: 34044026
Diabet Med. 2022 May;39(5):e14766
pubmed: 34890078
Diabetes Res Clin Pract. 2020 Apr;162:108092
pubmed: 32109519
Diabetes Res Clin Pract. 2018 Mar;137:137-148
pubmed: 29325774
BMJ. 2004 Jun 19;328(7454):1490
pubmed: 15205295
J Clin Epidemiol. 2013 Jul;66(7):726-35
pubmed: 23570745
BMJ. 2008 May 10;336(7652):1049-51
pubmed: 18467413
BMJ Open. 2022 Jun 10;12(6):e056400
pubmed: 35688599
Molecules. 2022 Jul 05;27(13):
pubmed: 35807558
JAMA. 2022 Feb 8;327(6):534-545
pubmed: 35133415
J Clin Epidemiol. 2013 Jul;66(7):719-25
pubmed: 23312392
N Engl J Med. 2021 Aug 5;385(6):503-515
pubmed: 34170647
Cardiovasc Diabetol. 2023 Mar 16;22(1):59
pubmed: 36927451
Eye (Lond). 2022 Aug;36(8):1523-1526
pubmed: 35145277
BMJ. 2016 Jun 30;353:i2089
pubmed: 27365494
Cureus. 2022 Jun 21;14(6):e26180
pubmed: 35891859